BACKGROUND: Worldwide metastatic colorectal cancer is the second most common cause of death attributable to cancer. Advances in molecular dia-gnostics led to recognition of several molecular subtypes of this disease. BRAF mutated colorectal cancer define specific challenging subgroup associated with dismal prognosis, lower rate of response rate, shorter progression free survival and overall survival. Current treatment choices are associated with poor outcomes. For the first line treatment doublet or triplet chemotherapy plus antiangiogenic antibody is used. To date, there were no reasonable treatment options in the second line settings. Recently published BEACON trial sets new standard of treatment with combination of encorafenib plus cetuximab, which led to significantly longer overall survival and overall response compared to standard therapy. Furthermore, this combination has shown well-tolerated safety profile with manageable toxicities. PURPOSE: The aim of this article is a review of current treatment options for BRAF mutated colorectal cancer.

• Klíčová slova
• BEACON, BRAF V600E, binimetinib, cetuximab, encorafenib, metastatic colorectal cancer,
• MeSH
• cetuximab aplikace a dávkování   MeSH
• karbamáty aplikace a dávkování   MeSH
• kolorektální nádory farmakoterapie   genetika   mortalita   patologie   MeSH
• lidé MeSH
• mutace MeSH
• protokoly protinádorové kombinované chemoterapie terapeutické užití   MeSH
• protoonkogenní proteiny B-Raf antagonisté a inhibitory   genetika   MeSH
• sulfonamidy aplikace a dávkování   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH
• Názvy látek
• BRAF protein, human MeSH Prohlížeč
• cetuximab MeSH
• encorafenib MeSH Prohlížeč
• karbamáty MeSH
• protoonkogenní proteiny B-Raf MeSH
• sulfonamidy MeSH